“…Also, the greater residence time in the target ocular tissues permits less frequent dosing, which increases adherence among patients with chronic conditions. [3][4][5] This new formulation of timolol maleate was evaluated in a small group of healthy subjects 13 and, subsequently, in a larger clinical trial with patients diagnosed with either openangle glaucoma or ocular hypertension. 14 Mundorf and associates 14 evaluated, in a double-masked, randomized cross-over study, the systemic bioavailability of timolol maleate with sorbic acid, timolol-LA (TLA, Istalol ® ), compared to that of generic timolol maleate ophthalmic solution (TIM).…”